- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05522660
Immunterapi eller målrettet terapi med eller uden stereootaktisk strålekirurgi til patienter med hjernemetastaser fra melanom eller ikke-småcellet lungekræft (USZ-STRIKE)
Et multicenter randomiseret åbent fase III-studie af stereootaktisk radiokirurgi, ud over standard systemisk terapi til patienter med metastatisk melanom eller nyligt diagnosticeret metastatisk NSCLC og asymptomatiske eller oligosymptomatiske hjernemetastaser
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymptomatic brain metastases from melanoma or NSCLC. This proposed randomised phase III clinical study addresses one of the most controversial issues in the current approach to patients with brain mets: the timing of SRS in patients eligible for systemic immune checkpoint inhibition or targeted therapy in order to guide therapeutic options as to what strategy allows the best compromise between best survival and best QoL.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Heidi Roschitzki-Voser, Dr.
- Telefonnummer: +41 31 511 94 18
- E-mail: heidi.roschitzki@etop.ibcsg.org
Undersøgelse Kontakt Backup
- Navn: Susanne Roux
- Telefonnummer: +41 31 511 94 17
- E-mail: susanne.roux@etop.ibcsg.org
Studiesteder
-
-
-
London, Det Forenede Kongerige
- Rekruttering
- Royal Marsden (Sutton)
-
Kontakt:
- Mary O'Brian
- E-mail: mary.obrien@rmh.nhs.uk
-
Manchester, Det Forenede Kongerige
- Rekruttering
- Christie NHS Manchester
-
Kontakt:
- Sarah Hughes
- E-mail: sarah.hughes91@nhs.net
-
-
-
-
-
Amsterdam, Holland
- Rekruttering
- NKI-AVL
-
Kontakt:
- Paul Baas
- E-mail: p.baas@nki.nl
-
-
-
-
-
Naples, Italien
- Rekruttering
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
-
Kontakt:
- Paolo Ascierto
- E-mail: p.ascierto@istitutotumori.na.it
-
Padova, Italien
- Ikke rekrutterer endnu
- Instituto Oncologico Veneto IRCCS
-
Kontakt:
- Luisa Piccin
- E-mail: luisa.piccin@iov.veneto.it
-
Perugia, Italien
- Rekruttering
- Santa Maria della Misericordia Hospital
-
Kontakt:
- Mario Mandala
- E-mail: mario.mandala@unipg.it
-
Roma, Italien
- Rekruttering
- Istituto Nazionale Tumori "Regina Elena"
-
Kontakt:
- Gabriele Minuti
- E-mail: gabriele.minuti@ifo.it
-
Rome, Italien
- Rekruttering
- Policlinico Umberto 1
-
Kontakt:
- Giuseppe Minniti
- E-mail: giuseppe.minniti@uniroma1.it
-
Siena, Italien
- Rekruttering
- Azienda ospedaliero-universitaria Senese Siena
-
Kontakt:
- Anna Maria di Giacomo
- E-mail: a.m.digiacomo@ao-siena.toscana.it
-
-
-
-
-
Bern, Schweiz
- Rekruttering
- Inselspital
-
Kontakt:
- Ekin Ermis
- E-mail: ekin.ermis@insel.ch
-
Winterthur, Schweiz
- Rekruttering
- Kantonsspital Winterthur
-
Kontakt:
- Natalie Fischer
- E-mail: natalie.fischer@ksw.ch
-
Zurich, Schweiz
- Rekruttering
- Universitätsspital Zürich
-
Kontakt:
- Michael Weller, Prof.
- E-mail: Michael.Weller@usz.ch
-
-
-
-
-
Barcelona, Spanien
- Rekruttering
- Vall Hebron Institute of Oncology (VHIO)
-
Kontakt:
- Patricia Irano
- E-mail: piranzo@vhio.net
-
Majadahonda, Spanien
- Rekruttering
- Hospital Puerta de Hierro
-
Kontakt:
- Ana Collazo Lorduy
- E-mail: anaclorduy@gmail.com
-
Valencia, Spanien
- Rekruttering
- Hospital La Fe
-
Kontakt:
- Oscar Jose Juan Vidal
- E-mail: juan_osc@gva.es
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Most important inclusion criteria:
-
Newly diagnosed, previously untreated (except for surgery, see below) asymptomatic or oligo-symptomatic brain metastases, e.g., controlled symptomatic seizure disorder. Note: patients with neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week are not considered oligo-symptomatic.
-
Requirements for brain metastases:
-
Brain metastases must be previously untreated, except for surgery.
-
Prior surgery (including biopsies, resection, and cyst aspiration) for brain metastases is allowed. Residual and measurable disease after surgery is not required, but surgery must have confirmed the diagnosis. An MRI performed within 72 hours post-surgery should be available.
-
Number and size of metastases at diagnosis of brain metastases:
- Maximum 1-10 brain metastases at screening
- At least one brain metastasis must be of ≥5 mm in diameter
- In case of 1-4 brain metastases:
- Longest diameter of largest brain metastasis must be ≤30 mm
- In case of 5-10 brain metastases:
- Largest metastasis must be ≤10 mL in volume and longest diameter must be ≤30 mm
- Maximum cumulative brain metastases volume must be ≤30 mL
-
Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC
-
Requirements for patients with melanoma:
-
Prior treatment, including treatment with immune-checkpoint inhibitors is permitted, but brain metastases must be newly diagnosed and previously untreated (except for surgery).
-
BRAF-mutation status, locally assessed, should be known (previous adjuvant BRAF-targeted therapy is allowed).
-
Requirements for patients with NSCLC:
-
Newly diagnosed, treatment-naïve (except for prior surgery) metastatic NSCLC, with or without a targetable oncogenic driver alteration.
-
Known PD-L1 expression status (from primary tumour or from a metastatic lesion, including brain)
-
Known driver mutation status (from primary tumour or from a metastatic lesion, including brain).
-
Age of 18 years or older
-
Karnofsky performance status of 60 or more
-
Life expectancy >12 weeks
-
Patients must be candidates for systemic treatment, within the defined cohorts (melanoma: cohorts 1a and 1b; NSCLC: cohorts 2a and 2b).
-
Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 7 days before randomisation.
-
Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
Most important exclusion criteria:
- Confirmed or probable leptomeningeal metastases according to EANO ESMO criteria
- Symptomatic brain metastases at time of randomisation, e.g., neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week.
- Patients must be off steroids or on a stable dose of ≤4 mg dexamethasone equivalent at randomisation.
- Patients experiencing seizures controlled by anti-epileptic drugs are eligible.
- Prior whole brain irradiation or focal radiation therapy to the brain
- Prior systemic treatment for brain metastases
- Contra-indication for SRS
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
- Women who are pregnant or in the period of lactation.
- Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Standard systemic treatment with stereotactic radiosurgery (SRS)
Arm A |
Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of >20 mm or for >4 brain metastases. For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation. Systemic therapy follows the current standard of care, according to the type of the primary tumour.
Andre navne:
|
|
Aktiv komparator: Standard systemic treatment without stereotactic radiosurgery
Arm B |
Systemic therapy follows the current standard of care, according to the type of the primary tumour.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
CNS-specific PFS, locally assessed as per iRANO criteria
Tidsramme: from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
The primary objective of the study is to assess the efficacy in terms of CNS-specific progression-free survival (PFS) of the combination of standard systemic treatment plus SRS versus standard systemic treatment alone in patients with newly diagnosed and untreated (except surgery) asymptomatic or oligo-symptomatic brain metastases from melanoma or non-small cell lung cancer, with indication for systemic therapy. |
from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studiestol: Michael Weller, MD, University of Zurich
- Studiestol: Rolf Stahel, MD, ETOP IBCSG Partners Foundation
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Lungesygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Lungeneoplasmer
- Hudsygdomme
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Neuroendokrine tumorer
- Nevi og melanomer
- Neoplasmer i huden
- Hud- og bindevævssygdomme
- Karcinom, ikke-småcellet lunge
- Melanom
- Antineoplastiske midler, immunologiske
- Antineoplastiske midler
- Molekylære mekanismer for farmakologisk virkning
- Undersøgelsesteknikker
- Terapeutik
- Kirurgiske procedurer, operative
- Farmakologiske handlinger
- Kemiske handlinger og anvendelser
- Terapeutiske anvendelser
- Strålebehandling
- Stereotaksiske teknikker
- Neurokirurgiske procedurer
- Immune Checkpoint-hæmmere
- Radiokirurgi
Andre undersøgelses-id-numre
- ETOP 19-21
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .